Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant Staphylococcus aureus: A Retrospective Single-Centre Experience

Background: Our aim was to describe the clinical outcome and safety of the sequential treatment with off-label dalbavancin in patients with spondylodiscitis that is caused by methicillin-resistant Staphylococcus aureus (MRSA). Methods: We retrospectively included all patients >18 years of age wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazzitelli, Maria, Gatti, Milo, Scaglione, Vincenzo, Mengato, Daniele, Trevenzoli, Marco, Sattin, Andrea, Pea, Federico, Cattelan, Anna Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598816/
https://www.ncbi.nlm.nih.gov/pubmed/36290035
http://dx.doi.org/10.3390/antibiotics11101377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598816/
https://www.ncbi.nlm.nih.gov/pubmed/36290035
http://dx.doi.org/10.3390/antibiotics11101377

Ejemplares similares